These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19032525)

  • 1. Change in coronary artery calcification score due to cinacalcet hydrochloride administration.
    Tsuruta Y; Ohbayashi T; Fujii M; Myochin H; Mizutani R; Narita M; Maeda K
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S34-7. PubMed ID: 19032525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.
    Floege J; Raggi P; Block GA; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Chertow GM;
    Nephrol Dial Transplant; 2010 Jun; 25(6):1916-23. PubMed ID: 20110249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
    Iseki K
    Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
    Kakuta T; Tanaka R; Hyodo T; Suzuki H; Kanai G; Nagaoka M; Takahashi H; Hirawa N; Oogushi Y; Miyata T; Kobayashi H; Fukagawa M; Saito A
    Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cinacalcet on vascular calcification in haemodialysis patients.
    Almirall J; Gallardo X; Castañé E
    Nephrol Dial Transplant; 2010 Aug; 25(8):2800. PubMed ID: 20501465
    [No Abstract]   [Full Text] [Related]  

  • 7. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
    Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
    J Clin Pathol; 2011 Sep; 64(9):756-60. PubMed ID: 21565858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study.
    Bellasi A; Reiner M; Pétavy F; Goodman W; Floege J; Raggi P
    J Heart Valve Dis; 2013 May; 22(3):391-9. PubMed ID: 24151766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient.
    Yamada S; Tsuruya K; Kitazono T
    Ther Apher Dial; 2013 Jun; 17(3):348-9. PubMed ID: 23735152
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis.
    Díez JJ; Miguel JL; Codoceo R; Iglesias P; Bajo MA; Sánchez C; Del Peso G; Gil F; Martinez-Ara J; Gancedo PG; Selgas R
    Nephrol Dial Transplant; 2008 Apr; 23(4):1387-95. PubMed ID: 18045826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal of cinacalcet at the time of renal transplantation is not a risk factor for allograft calcifications in the early posttransplantation period.
    Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Soler M; Campistol JM
    Transplant Proc; 2012 Oct; 44(8):2379-80. PubMed ID: 23026598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
    Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
    Kakuta T; Tanaka R; Kanai G; Sawaya A; Hirukawa T; Sato A; Saito A
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S20-7. PubMed ID: 19765255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.
    Dorsch O
    Nephrol Dial Transplant; 2007 Feb; 22(2):637-40. PubMed ID: 17095580
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients.
    Hirai T; Nakashima A; Takasugi N; Yorioka N
    Ther Apher Dial; 2010 Dec; 14(6):577-82. PubMed ID: 21118366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.